This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

This study has been completed.
Information provided by (Responsible Party):
Chromaderm, Inc. Identifier:
First received: August 20, 2002
Last updated: January 30, 2017
Last verified: January 2017
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.

Condition Intervention Phase
Diabetic Nephropathy Drug: LY333531 Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: The Effect of LY333531 on Albuminuria in Patients With Type 2 Diabetes A Pilot Clinical Trial

Resource links provided by NLM:

Further study details as provided by Chromaderm, Inc.:

Actual Study Start Date: July 16, 2002
Study Completion Date: April 28, 2004
Primary Completion Date: April 28, 2004 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Type 2 diabetes mellitus
  • Greater than or equal to 30 years of age
  • Albumin to Creatinine ratio (greater than 200 mg/g and less than 2000 mg/g) 4)Without language barrier.

Exclusion Criteria:

  • Serum Creatinine greater than 2.0 mg/dl males or greater than 1.7 mg/dl females
  • B/P greater than 150 systolic and greater than 90 diastolic
  • Hemoglobin Alc greater than 11%
  • Liver Function Tests 2 times upper limit of normal
  • Poor medical or psychiatric risk.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00044148

United States, California
La Jolla, California, United States
Walnut Creek, California, United States
United States, Florida
Jacksonville, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
United States, Kentucky
Lexington, Kentucky, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Waltham, Massachusetts, United States
United States, Minnesota
Minneapolis, Minnesota, United States
United States, Missouri
St Louis, Missouri, United States
United States, New York
New York, New York, United States
United States, North Carolina
Greenville, North Carolina, United States
United States, Texas
Dallas, Texas, United States
United States, Washington
Seattle, Washington, United States
Spokane, Washington, United States
Sponsors and Collaborators
Chromaderm, Inc.
  More Information

Responsible Party: Chromaderm, Inc. Identifier: NCT00044148     History of Changes
Other Study ID Numbers: 6249
Study First Received: August 20, 2002
Last Updated: January 30, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Chromaderm, Inc.:
Persistent Albuminuria

Additional relevant MeSH terms:
Diabetic Nephropathies
Kidney Diseases
Urologic Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 19, 2017